Topic Highlight
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jan 7, 2016; 22(1): 326-337
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.326
Table 1 Liver- or hepatocellular carcinoma - specific promoters in adeno-associated virus vectors
PromoterTargetDelivery geneRef.
CBALiverReporter, Flk-1, Mut, MUT, GFP[15,87-89]
TBGLiverCanine factor IX, IDS. Mut[15,90,91]
hEF1αLiverIFN-α[92]
hAATLiverhFIX, synMUT[15,93]
Mouse albuminLiverHGAA, tTA, EGFP[94]
Albumin + α fetoproteinHepatocellular carcinomaHSV-TK[35,95]
hTERTHepatocellular carcinomaTRAIL[8]
survivinHepatocellular carcinomaTSLC1[70]
Table 2 Overview of clinical trials that use adenovirus vector for hepatocellular carcinoma therapy
AdenovirusPhaseTrialStatusRouteNotes
ADV-TKIINCT00300521CompleteditAs a single agent
TK99UNINCT00844623CompleteditAs a single agent
AdVhAFPI/IINCT00669136TerminatedimCombined with AFP and GM-CSF
AdVhAFPII/IIIA/IIIB/IVANCT00093548Withdrawnim and idCombined with AFP and GM-CSF
ADV-TKIINCT02202564CompletedIntrahepaticDouble-dose
Ad5CMV-p53INCT00003147TerminatedPercutaneous injectionAs a single agent
Adenovirus Type 5IIINCT01869088RecruitingArterial infusionCombined with TACE
rAd-p53IINCT02418988RecruitingArterial injectionCombined with TACE